Vascular remodeling and clinical resistance to antiangiogenic cancer therapy

When first conceived, antiangiogenic therapy for cancer offered the possibility of universal efficacy, low toxicity, and little possibility of resistance. Blockade of the vascular endothelial growth factor (VEGF) pathway has yielded the most promising results both in animal models and in patients. H...

Full description

Saved in:
Bibliographic Details
Published in:Drug resistance updates 2004-08, Vol.7 (4), p.289-300
Main Authors: Glade Bender, Julia, Cooney, Erin M., Kandel, Jessica J., Yamashiro, Darrell J.
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Angiopoietin
Animals
Antiangiogenesis
Bevacizumab
Clinical Trials as Topic
Drug Resistance, Neoplasm - drug effects
Humans
Neoplasms - drug therapy
Neoplasms - metabolism
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - metabolism
PDGF
Vascular remodeling
VEGF
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:When first conceived, antiangiogenic therapy for cancer offered the possibility of universal efficacy, low toxicity, and little possibility of resistance. Blockade of the vascular endothelial growth factor (VEGF) pathway has yielded the most promising results both in animal models and in patients. However, resistance to VEGF blockade has been found even when given in combination with chemotherapy or other antiangiogenic agents. This resistance is associated with remodeled vasculature and with increased expression of angiogenic factors, such as PDGF-B and angiopoietin-1, which may contribute to vessel stabilization. Future efforts must be directed towards the identification of factors associated with vascular remodeling in order to improve the efficacy of antiangiogenic therapy.
ISSN:1368-7646
1532-2084
DOI:10.1016/j.drup.2004.09.001